MNOV Medicinova Inc
- Stocks
- Healthcare
- NASDAQ: MNOV
Price (delayed)
$1.47
Market cap
$72.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.25
Enterprise value
$38.02M
Relative Growth:
Rel. Growth:
1
Relative Strength:
Rel. Strength:
46
Relative Valuation:
Rel. Valuation:
1
Relative Profitability:
Rel. Profitability:
6
MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S.
Highlights
The debt has contracted by 2.7% YoY and by 2.6% from the previous quarter
Medicinova's gross profit has shrunk by 98% YoY
The company's revenue has shrunk by 87% YoY
Key stats
What are the main financial stats of MNOV
Market
Valuations
Earnings
Shares outstanding
49.05M
Market cap
$72.1M
Enterprise value
$38.02M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.54
Price to sales (P/S)
535.65
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
282.49
Revenue
$134,599
Gross profit
$18,250
Operating income
-$13.3M
Net income
-$11.81M
EBIT
-$11.81M
EBITDA
-$11.61M
Free cash flow
-$10.05M
Per share
Balance sheet
Liquidity
EPS
-$0.25
EPS diluted
-$0.25
Free cash flow per share
-$0.2
Book value per share
$0.96
Revenue per share
$0
TBVPS
$0.82
Total assets
$49.82M
Total liabilities
$2.97M
Debt
$184,842
Equity
$46.86M
Working capital
$32.48M
Debt to equity
0
Current ratio
13.26
Quick ratio
12.99
Net debt/EBITDA
2.94
Margins
Efficiency
Dividend
EBITDA margin
-8,622.2%
Gross margin
13.6%
Net margin
-8,775.8%
Operating margin
-9,883%
Return on assets
-21.8%
Return on equity
-23.1%
Return on invested capital
-318.9%
Return on capital employed
-25%
Return on sales
-8,771.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MNOV stock price
How has the Medicinova stock price performed over time
Intraday
-2.65%
1 week
23.53%
1 month
13.95%
1 year
-5.77%
YTD
-30%
QTD
15.75%
Financial performance
How have Medicinova's revenue and profit performed over time
Revenue
$134,599
Gross profit
$18,250
Operating income
-$13.3M
Net income
-$11.81M
Gross margin
13.6%
Net margin
-8,775.8%
Medicinova's gross profit has shrunk by 98% YoY
The company's revenue has shrunk by 87% YoY
The gross margin has plunged by 86% YoY
MNOV's net income is down by 45% YoY and by 6% from the previous quarter
Price vs fundamentals
How does MNOV's price correlate with its fundamentals
Growth
What is Medicinova's growth rate over time
Valuation
What is Medicinova stock price valuation
P/E
N/A
P/B
1.54
P/S
535.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
282.49
MNOV's EPS has dropped by 56% year-on-year and by 9% since the previous quarter
The equity has declined by 18% year-on-year and by 6% since the previous quarter
The P/B is 12% lower than the 5-year quarterly average of 1.8 and 7% lower than the last 4 quarters average of 1.7
The company's revenue has shrunk by 87% YoY
Efficiency
How efficient is Medicinova business performance
Medicinova's return on equity has shrunk by 72% YoY and by 11% QoQ
The ROA has shrunk by 72% YoY and by 11% QoQ
MNOV's ROIC is down by 47% YoY and by 11% QoQ
Dividends
What is MNOV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MNOV.
Financial health
How did Medicinova financials performed over time
The quick ratio has contracted by 27% YoY and by 24% from the previous quarter
MNOV's current ratio is down by 27% year-on-year and by 25% since the previous quarter
The debt is 100% less than the equity
The equity has declined by 18% year-on-year and by 6% since the previous quarter
The debt has contracted by 2.7% YoY and by 2.6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.